



(12) **EUROPEAN PATENT SPECIFICATION**

(45) Date of publication and mention of the grant of the patent:  
**01.02.2006 Bulletin 2006/05**

(51) Int Cl.:  
**C12N 15/09 (2006.01) C07K 14/78 (2006.01)**  
**C07K 14/705 (2006.01)**

(21) Application number: **01912238.1**

(86) International application number:  
**PCT/JP2001/001871**

(22) Date of filing: **09.03.2001**

(87) International publication number:  
**WO 2001/066736 (13.09.2001 Gazette 2001/37)**

(54) **PROTEINS NECTIN-3**  
NECTIN-3 PROTEINE  
PROTEINES DU TYPE NECTINE 3

(84) Designated Contracting States:  
**DE FR GB**

(30) Priority: **09.03.2000 JP 2000006595**

(43) Date of publication of application:  
**13.02.2002 Bulletin 2002/07**

(73) Proprietors:  
• **Japan Science and Technology Agency**  
**Kawaguchi-shi,**  
**Saitama 332-0012 (JP)**  
• **JCR PHARMACEUTICALS Co., LTD.**  
**Ashiya-shi,**  
**Hyogo (JP)**

(72) Inventors:  
• **TAKAHASHI, Kenichi**  
**Kobe-shi,**  
**Hyogo 655-0854 (JP)**  
• **TAKAI, Yoshimi**  
**Kobe-shi,**  
**Hyogo 651-2102 (JP)**  
• **NAKANISHI, Hiroyuki**  
**Kobe-shi,**  
**Hyogo 651-2103 (JP)**  
• **SATO, Keiko**  
**Nishi-ku,**  
**Kobe-shi,**  
**Hyogo 651-2112 (JP)**

(74) Representative: **Webber, Philip Michael**  
**Frank B. Dehn & Co.,**  
**179 Queen Victoria Street**  
**London EC4V 4EL (GB)**

(56) References cited:

- **DATABASE EMBL [Online] 20 May 1999 (1999-05-20) "Homo sapiens mRNA, cDNA DKFZp566B0846" retrieved from EBI Database accession no. AL050071 XP002268762**
- **DATABASE EMBL [Online] 26 April 1999 (1999-04-26) "Stratagene mouse testis vi73c03 " retrieved from EBI Database accession no. AI614172 XP002268763**
- **DATABASE EMBL [Online] 16 March 1999 (1999-03-16) "Stratagene mouse testis m146h10 EST" retrieved from EBI Database accession no. AI428160 XP002268764**
- **DATABASE EMBL [Online] 1 November 1999 (1999-11-01) "Hypothetical protein fragment" retrieved from EBI Database accession no. Q9Y412 XP002268765**
- **AOKI JUNKEN ET AL: "Mouse homolog of poliovirus receptor-related gene 2 product, mPRR2, mediates homophilic cell aggregation" EXPERIMENTAL CELL RESEARCH, vol. 235, no. 2, 1997, pages 374-384, XP002268759 ISSN: 0014-4827**
- **MORRISON M E ET AL: "MOLECULAR CLONING AND EXPRESSION OF A MURINE HOMOLOG OF THE HUMAN POLIOVIRUS RECEPTOR GENE" JOURNAL OF VIROLOGY, vol. 66, no. 5, 1992, pages 2807-2813, XP002268760 ISSN: 0022-538X**
- **REYMOND N ET AL: "Human nectin3/PRR3: a novel member of the PVR/PRR/nectin family that interacts with afadin" GENE, ELSEVIER BIOMEDICAL PRESS. AMSTERDAM, NL, vol. 255, no. 2, 19 September 2000 (2000-09-19), pages 347-355, XP004217649 ISSN: 0378-1119**

Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).

- SATOH-HORIKAWA K ET AL: "Nectin-3, a New Member of Immunoglobulin-like Cell Adhesion Molecules That Shows Homophilic and Heterophilic Cell-Cell Adhesion Activities" JOURNAL OF BIOLOGICAL CHEMISTRY, AMERICAN SOCIETY OF BIOLOGICAL CHEMISTS, BALTIMORE, MD, US, vol. 275, no. 14, 7 April 2000 (2000-04-07), pages 10291-10299, XP002198184 ISSN: 0021-9258
- DATABASE EMBL [Online] 7 August 2000 (2000-08-07) "Homo sapiens nectin 3 mRNA, complete cds." retrieved from EBI Database accession no. AF282874 XP002268766
- LOPEZ MARC ET AL: "The human poliovirus receptor related 2 protein is a new hematopoietic/endothelial homophilic adhesion molecule" BLOOD, vol. 92, no. 12, 15 December 1998 (1998-12-15), pages 4602-4611, XP002268761 ISSN: 0006-4971
- TAKAHASHI K. ET AL.: 'An immunoglobulin-like cell adhesion molecule recruited to cadherin-based adherens junctions through interaction with Afadin, a PDZ domain-containing protein' J. CELL. BIOL. vol. 145, no. 3, 1999, pages 539 - 549, XP002941478
- MIYAHARA M. ET AL.: 'Interaction of nectin with afadin is necessary for its clustering at cell-cell contact sites but not for its cis dimerization or trans interaction' J. BIOL. CHEM. vol. 275, no. 1, 2000, pages 613 - 618, XP002941479
- ASAKURA T. ET AL.: 'Similar and differential behaviour between the nectin-afadin-ponsin and cadherin-catenin systems during the formation and disruption of the polarized junctional alignment in epithelial cells' GENES CELLS vol. 4, no. 10, 1999, pages 573 - 581, XP002941480

**Description****TECHNICAL FIELD**

5 **[0001]** The invention of this application relates to a novel protein nectin-3 that participates in cadherin-based cell-cell adherens junctions, and to gene-engineering materials for obtaining and utilizing the protein.

**BACKGROUND ART**

10 **[0002]** Cell-cell adhesion systems to be formed by transmembrane proteins, such as adhesion molecules, receptors and channels play an important role in various cell-level phenomena such as cell-cell adhesion, cell movement and cell morphology determination in animal individuals. Above all, cell-cell adherens junctions (AJs) bear a role indispensable for histocompatibility. Evidence is increasing to say that AJs further participate in controlling cell propagation and morphologic tissue formation, in addition to their mechanistic role as above. It has become clarified that many F-actin-binding proteins play a role as a linker to link actin cytoskeletons to adhesion molecules. However, the molecule-level understanding of AJs is insufficient, and it is not clear as to which molecules may bind actin cytoskeletons to cell membranes.

15 **[0003]** To clarify this, the inventors of this application have isolated some novel F-actin-binding proteins from rats' brains, analyzed the structure of the protein especially specific to neurocytes and abundantly existing in synapses, and named it "neurabin", for which the applicant already filed a patent application (Japanese Patent Application No. 276784/1998). Further, the inventors of this application have individually isolated 1-afadin, a novel F-actin-binding protein, and ponsin, a protein that binds with 1-afadin, for both of which the applicant filed patent applications (for 1-afadin, Japanese Patent Application No. 89572/ 1999; for ponsin, Japanese Patent Application No. 174687/1999). Still further, the inventors of this application have identified novel proteins, nectin-1 $\alpha$ , 1 $\beta$  and nectin-2 $\alpha$ , 2 $\delta$  that function for cadherin-based AJ formation along with afadin (J. Cell Biol., 145:539-549, 1999). They have found that these nectin-1, -2 are Ca<sup>2+</sup>-independent immunoglobulin-like adhesion molecules and act on AJ formation in one system along with afadin and ponsin (Genes Cells 4:573-581, 1999; J. Biol. Chem., 275:613-618,2000).

25 **[0004]** Clarifying the molecular mechanism of cell-cell adhesion will make it possible to clarify, for example, the mechanism of humectation and metastasis of carcinoma, and is expected to be applicable to diagnosis of carcinoma for its malignancy and to a method for treating cases with carcinoma and also to development of medicines for carcinoma. For clarifying it, it is necessary to clarify all the details of the molecules that participate in cell-cell adhesion.

30 **[0005]** The invention of this application has been made in consideration of the current situation as above, and its one object is to provide a novel protein that participates in cell-cell adherens junctions.

**[0006]** Another object of the invention is to provide a gene-engineering material for producing the protein.

**DISCLOSURE OF THE INVENTION**

35 **[0007]** To solve the problems noted above, this application provides a protein nectin-3 having the amino acid sequence of any of SEQ ID NO: 2, 4 or 6.

40 **[0008]** The protein nectin-3 is derived from mice, including three splicing variants expressed by mouse genomic gene (these proteins are hereinafter referred to as nectin-3 $\alpha$ , nectin-3 $\beta$ , nectin 3 $\gamma$ ).

**[0009]** This application also provides a polynucleotide that encodes the protein nectin-3. The polynucleotide includes genomic DNA, mRNAs and cDNAs.

**[0010]** This application further provides cDNAs each encoding the three types of nectin-3, or that is, polynucleotides each having the base sequence of any of SEQ ID NO:1,3 or 5.

45 **[0011]** This application still further provides a recombinant vector having any of these polynucleotides.

**[0012]** This application still further provides an antibody against any of the three types of protein nectin-3.

**[0013]** Like nectin-1 and nectin-2, the protein nectin-3 of this invention is common to all mammals, existing in any and every mammal. Therefore, the protein nectin-3 and the polynucleotide encoding it are not limited to only mouse-derived ones.

50

**BRIEF DESCRIPTION OF THE DRAWINGS**

**[0014]** Fig. 1 is to compare the amino acid sequences of nectin-3 $\alpha$ , -3 $\beta$  and -3 $\gamma$ . The black background indicates the identical sequence among the three variants; the gray background indicates the identical sequence between nectin-3 $\beta$  and -3 $\gamma$ ; the underline indicates the signal peptide; the double underlines indicate the transmembrane regions; and the asterisks indicate the glycosylated sites in asparagine.

55 **[0015]** Fig. 2 shows the experimental data of trans homo-interaction of nectin-3 $\alpha$ . (A) indicates the expression level of nectin-3 $\alpha$ , for which a cell lysate was subjected to development in SDS-PAGE followed by Western blot analysis with

a polyclonal anti-nectin-3 $\alpha$  antibody. (B) indicates cell aggregation activities of parental L cells (o) and nectin-3 $\alpha$ -expressing L cells (•). (C) indicates cell aggregation activities of parental L cells (C1) and nectin-3 $\alpha$ -expressing L cells (C2). The bar is 100  $\mu$ m.

[0016] Fig. 3 shows the experimental data of cis homo-dimerization of nectin-3 $\alpha$ . Nectin-3 $\alpha$ -expressing cells were incubated in the presence or absence of BS3; each cell lysate was subjected to development in SDS-PAGE followed by Western blot analysis with a polyclonal anti-nectin-3 $\alpha$  antibody. The arrow indicates the monomer; and the arrowhead indicates the dimer.

[0017] Fig. 4 shows the experimental data of mixed-cell aggregation activities of labeled nectin-1 $\alpha$ -expressing L cells and unlabeled nectin-2 $\alpha$ -expressing L cells (A1 to A3), labeled nectin-3 $\alpha$ -expressing L cells and unlabeled nectin-1 $\alpha$ -expressing L cells (B1 to B3), and labeled nectin-3 $\alpha$ -expressing L cells and unlabeled nectin-2 $\alpha$ -expressing L cells (C1 to C3). A1, B1 and C1 are the images in interference contrast microscopy; A2, B2 and C2 are the images in fluorescence microscopy; A3, B3 and C3 are the data in statistical analysis. The bars are 40  $\mu$ m.

[0018] Fig. 5 shows the images in immunofluorescence microscopy of co-cultured two L cell lines of nectin-1 $\alpha$ -expressing L cells and -2 $\alpha$ -expressing L cells (A1 to A3), nectin-3 $\alpha$ -expressing L cells and -1 $\alpha$ -expressing L cells (B1 to B3), and nectin-3 $\alpha$ -expressing L cells and -2 $\alpha$ -expressing L cells (C1 to C3). In A1 and B2, seen is nectin-1 $\alpha$ ; in A2 and C2, nectin-2 $\alpha$ ; in B1, nectin-3 $\alpha$  (monoclonal antibody); in C1, nectin-3 $\alpha$  (polyclonal antibody); and in A3, B3 and C3, merged. The bars are 10  $\mu$ m.

[0019] Fig. 6 shows the experimental data of trans hetero-interaction affinity, for which a cell composition (labeled and unlabeled cells) of two-cell aggregates was quantitatively analyzed. A indicates the data of labeled nectin-1 $\alpha$ -expressing L cells and unlabeled nectin-2 $\alpha$ -expressing L cells; B indicates the data of labeled nectin-3 $\alpha$ -expressing L cells and unlabeled nectin-1 $\alpha$ -expressing L cells; and C indicates the data of labeled nectin-3 $\alpha$ -expressing L cells and unlabeled nectin-2 $\alpha$ -expressing L cells.

[0020] Fig. 7 shows the experimental data of cis hetero-dimerization nectin-3 $\alpha$  with nectin-1 $\alpha$  or -2 $\alpha$ . A is for comparison of cis dimerization. A1 indicates the data of nectin-1 $\alpha$ -expressing L cells (lane 1) and -1 $\alpha$ /3 $\alpha$ -expressing L cells (lane 2); A2 indicates the data of nectin-2 $\alpha$ -expressing L cells (lane 1) and -2 $\alpha$ /3 $\alpha$ -expressing L cells (lane 2). B shows the data of immunoprecipitation. B1 indicates the data of nectin-1 $\alpha$ /3 $\alpha$ -expressing L cells; B2 indicates the data of nectin-2 $\alpha$ /3 $\alpha$ -expressing L cells. The cell extract is in lane 1; the supernatant is in lane 2; the precipitate is in lane 3. The arrows indicate monomers; and the arrowheads indicate the dimers.

[0021] Fig. 8 shows the experimental data of nectin-3 distribution in tissues. A shows the data of Northern blot analysis of nectin-1 (A1), nectin-2 (A2) and nectin-3 (A3). B shows the data of Northern blot analysis of nectin-3 $\beta$  (B1), nectin-3 $\beta$  (B2) and nectin-3 $\gamma$  (B3). Lane 1 is in heart; lane 2 is in brain; lane 3 is in spleen; lane 4 is in lung, lane 5 is in liver, lane 6 is in skeletal muscle; lane 7 is in kidney; and lane 8 is in testis.

[0022] Fig. 9 shows the experimental data of intracellular localization of nectin-3 $\alpha$  in mouse small intestine absorptive epithelia. In A, seen is nectin-3 $\alpha$ ; in B, nectin-2; and in C, merged. The asterisks indicate the inner space of small intestines. The bar is 10  $\mu$ m.

[0023] Fig. 10 shows the experimental data of direct binding of afadin to nectin-3 $\alpha$ . The arrow indicates a fusion protein, GST-nectin-3 $\alpha$ -CP; and the arrowhead indicates a fusion protein, MBP-afadin-PDZ.

## BEST MODE FOR CARRYING OUT THE INVENTION

[0024] A mouse protein, nectin-3 $\alpha$  is encoded by 1650 bp cDNA having the base sequence of SEQ ID NO: 1, and this has the sequence of 549 amino acids as in SEQ ID NO: 2. The complete cDNA of the nectin-3 $\alpha$  has the base sequence of 2178 bp as in SEQ ID NO: 7.

[0025] Nectin-3 $\beta$  is a protein encoded by 1533 bp cDNA having the base sequence of SEQ ID NO: 3, and this has the sequence of 510 amino acids as in SEQ ID NO: 4.

[0026] Nectin-3 $\gamma$  is a protein encoded by 1317 bp cDNA having the base sequence of SEQ ID NO: 5, and this has the sequence of 435 amino acids as in SEQ ID NO: 6.

[0027] These proteins nectin-3 can be obtained in any known method, for example, according to a method of isolating them from mouse and other mammal tissues; according to a method that comprises preparing peptides through chemical synthesis based on the amino acid sequences provided by this invention; or according to a method of recombinant DNA technology using the polynucleotides provided by this invention. Concretely, nectin-3 may be obtained through recombinant DNA technology as follows: An RNA is prepared through in-vitro transcription from a vector having a polynucleotide that encodes nectin-3, and the nectin-3 is expressed in vitro through in-vitro translation using the RNA as a template. In the case of the polynucleotide encoding the nectin-3 being recombined with a suitable expression vector in a known manner, the nectin-3 encoded by the polynucleotide can be abundantly expressed in *E. coli*, *B. subtilis*, yeast, animal or plant cells, etc.

[0028] The protein nectin-3 of this invention can be expressed in microorganisms such as *E. coli*, in the following manner The polynucleotide of this invention that encodes the protein is inserted into an expression vector having an

origin replicable in microorganisms, a promoter, a ribosome-binding site, a DNA cloning site and a terminator to construct a recombinant expression vector, then host cells are transformed with the expression vector; and the resulting transformant cells are cultured. In that manner, the nectin-3 encoded by the polynucleotide can be abundantly produced in microorganisms. Alternatively, it may be expressed in the form of a fusion protein with any other protein segment. The resulting fusion protein is cleaved with a suitable protease, and only the protein segment encoded by the polynucleotide can be obtained.

**[0029]** The protein nectin-3 of this invention can be expressed in animal cells in the following manner: The polynucleotide of this invention that encodes the protein is recombined with an expression vector for animal cells having a promoter, a splicing region and a poly(A)-addition site, and the recombinant vector is introduced into animal cells, whereby the protein nectin-3 of this invention can be expressed in the thus-transformed animal cells.

**[0030]** The mouse protein nectin-3 obtained according to the method as above can be used, for example, as an antigen to form an antibody that specifically recognizes this protein.

**[0031]** Peptide fragments (of at least 5 amino acid residues) having any partial amino acid sequence of the amino acid sequence of SEQ ID NO: 2, 4 or 6, are also usable as an antigen for constructing the antibody.

**[0032]** The polynucleotide of this invention is a genomic gene of mammals that encodes any of the above-mentioned protein nectin-3 $\alpha$ ,  $\beta$  or  $\gamma$ . For example, it can be isolated from known genomic libraries, using the polynucleotide having the base sequence of any of SEQ ID NO: 1, 3 or 5 or its partial sequence as a probe.

**[0033]** A polynucleotide of this invention may be cDNA characterized by having the base sequence of SEQ ID NO: 1, 3 or 5, and it encodes any of the above-mentioned nectin-3 $\alpha$ ,  $\beta$  or  $\gamma$ . Clones of the polynucleotides of this invention can be obtained with ease. Concretely, using an oligonucleotide probe synthesized on the basis of the base sequence of SEQ ID NO: 1, 3 or 5, mouse and other mammal cDNA libraries are screened. Alternatively, using the oligonucleotides as primers, the intended polynucleotides can be synthesized through polymerase chain reaction (PCR).

**[0034]** The antibody of this invention can be obtained as a polyclonal antibody or a monoclonal antibody in any known method of using the protein nectin-3 itself or its partial peptide as an antigen.

**[0035]** The following Examples are to show the experimental data to confirm the structure and the function of the nectin-3 of this invention.

## EXAMPLES

### 1. Procedures

#### 1.1 Molecular Cloning of Mouse Nectin-3 cDNAs

**[0036]** From the EST database, three different types of mouse EST clones (AI1428160, AA492633, AA497887), which are similar to but are not the same as nectin-1 and -2, were amplified from a mouse brain cDNA (Clontech). Using the mixture of these cDNAs as a probe, a mouse cDNA library (Stratagene) was screened to obtain a full-length cDNA. For its DNA sequencing, used was a DNA sequencer (ABI 373).

#### 1.2 Construction of Nectin-3 Expression Vectors

**[0037]** Vectors pCAGIPuro (J. Biol. Chem., 275: 613-618, 2000), pCAGIPuro-FLAG, p-GEX-KG (Anal. Biochem., 192: 262-267, 1991), pMal-C2 (New England Biolabs Inc.) and pFastBac1-Msp-Fc (J. Cell. Biol., 145: 539-549, 1999) were used for constructing nectin-3 expression vectors mentioned below. The pCAGIPuro-FLAG was constructed by subcloning a prepro-trypsin signal peptide and the FLAG epitope of p FLAG-CMV1 (Eastman Kodak) into pCAGIPuro.

- (a) pCAGIPuro-nectin-3 $\alpha$ : 1-549 amino acids (full length) of SEQ ID NO: 2,
- (b) pCAGIPuro-FLAG-nectin-3 $\alpha$ : 56-549 amino acids of SEQ ID NO: 2,
- (c) GST-nectin-3 $\alpha$ -CP: 433-549 amino acids of SEQ ID NO: 2 (cytoplasmic region),
- (d) GST-nectin-3 $\alpha$ -CP- $\Delta$ C: 433-545 amino acids of SEQ ID NO: 2 (deletion of the C-terminal four amino acid residues),
- (e) GST-nectin-3 $\gamma$ -CP: 397-438 amino acids of SEQ ID NO: 6 (cytoplasmic region),
- (f) pFastBac1-Msp-Fc-nectin-3 $\alpha$ -EX: 56-400 amino acids of SEQ ID NO: 2 (extracellular region)

#### 1.3 Construction of Transformant Cells

**[0038]** L cells (obtained from the Kyoto University) were cultured in a 10 % fetal calf serum-containing DMEM medium to prepare parental L cells for transformation. Full-length human nectin-1 $\alpha$ -expressing L cells (nectin-1 $\alpha$ -L cells) and full-length mouse nectin-2 $\alpha$ -expressing L cells (nectin-2 $\alpha$ -L cells) were constructed according to the method described

## EP 1 179 592 B1

in references (J. Cell Biol., 145: 539-549, 1999; J. Biol. Chem., 275: 613-618, 2000). Full-length mouse nectin-3 $\alpha$ -expressing L cells (nectin-3 $\alpha$ -L cells) were constructed, using a recombinant vector pCAGIPuro-nectin-3 $\alpha$ . Nectin-1 $\alpha$  and FLAG-nectin-3 $\alpha$ -coexpressing L cells (nectin-1 $\alpha$ /3 $\alpha$ -L cells), and nectin-2 $\alpha$  and FLAG-nectin-3 $\alpha$ -coexpressing L cells (nectin-2 $\alpha$ /3 $\alpha$ -L cells) were constructed by transfecting the nectin-1 $\alpha$ -L cells and the nectin-2 $\alpha$ -L cells, respectively, with pCAGIPuro-FLAG-nectin-3 $\alpha$ , using a lipofectamine reagent (GIBCO BRL). Each cell line was cultured for 1 day, replated, and selected by culturing in the presence of 5  $\mu$ g/ml of puromycin (Sigma Chemical Co.).

### 1.4 Preparation of Antibodies:

**[0039]** A rabbit antiserum (polyclonal antibody) against nectin-3 $\alpha$  was raised against an antigen, GST-nectin-3 $\alpha$ -CP. A rat monoclonal antibody against nectin-3 was raised against an antigen, fusion protein of the extracellular region of nectin-3 $\alpha$  with IgG Fc. A rabbit polyclonal anti-nectin-1 $\alpha$  antibody was prepared according to the method described in a reference (J. Cell Biol., 145: 539-549, 1999). Another rabbit polyclonal anti-nectin-1 $\alpha$  antibody was raised against an antigen, synthetic peptide corresponding to the amino acid sequence 450-468 of nectin-1 $\alpha$ , according to the method described in the reference (J. Cell Biol., 145: 539-549, 1999). A rat monoclonal anti-nectin-2 antibody was prepared according to the method described in references (J. Cell Biol., 145: 539-549, 1999; Exp. Cell Res., 235: 374-384, 1997); and mouse monoclonal and rabbit polyclonal anti-1-afadin antibodies were prepared according to the method described in references (J. Cell Biol., 139: 517-528, 1997; Oncogene 18: 1609-1618, 1999). A rat monoclonal anti-E-cadherin antibody was obtained from Dr. Takeichi (Kyoto University). A mouse monoclonal anti-FLAG antibody was bought from Eastman Kodak.

### 1.5 Other Procedures

**[0040]** Cell aggregation assay was done according to the method described in references (J. Cell Biol., 145: 539-549, 1999; J. Biol. Chem., 275: 613-618, 2000). For mixed-cell aggregation assay between two different L cell lines, one L cell line was prelabeled with Dil (Molecular Probe Inc., USA), as described (J. Cell Biol., 103: 171-187, 1986).

**[0041]** Chemical cross-linking was done according to the method described in references (Blood 92: 4602-4611, 1998; J. Biol. Chem., 275: 613-618, 2000). Immunoprecipitation was performed according to the method described in references (J. Cell Biol., 145: 539-549, 1999; J. Biol. Chem., 275: 613-618, 2000). Immunofluorescence microscopy of cultured cells was done according to the method described in references (J. Cell Biol., 139: 517-528, J. Cell Biol., 145: 539-549, 1999; J. Biol. Chem., 275: 613-618, 2000). Protein concentrations were determined with bovine serum albumin as a control, according to the method described in a reference (Anal. Biochem., 72: 248-254, 1976). SDS-PAGE was done as described (Nature, 227: 680-685, 1970).

**[0042]** Affinity chromatography was performed as follows: The MBP-fusion protein of the PDZ domain of afadin was immobilized on amylose resin beads (New England Biolabs Inc.). GST-nectin-3 $\alpha$ -CP and GST-nectin-3 $\alpha$ -CP- $\Delta$ C were separately applied to the affinity beads. After extensively washed with PBS (containing 0.1 % Triton X-100), the beads were subjected to elution with PBS (containing 20 mM maltose, 0.1 % Triton X-100).

## 2. Results

### 2.1 Cloning and Characterization of Nectin-3 cDNAs

**[0043]** The cDNA clone obtained from the mouse cDNA library has the base sequence of SEQ ID NO: 7, and encoded a protein (calculated molecular weight 60,580) comprising 549 amino acids (SEQ ID NO: 2) in the 1647 bp coding region (SEQ ID NO: 1). This clone contained all the above-mentioned EST clones. The protein was named nectin-3 $\alpha$ .

**[0044]** The amino acid sequence of The nectin-3 $\alpha$  had an N-terminal hydrophobic signal peptide (1-55 amino acids of SEQ ID NO: 2) and a transmembrane region (405-421 amino acids of SEQ ID NO: 2). The sites for N-linked glycosylation were detected at 73, 83, 125, 186, 222 and 331 amino acids. The nectin-3 contained three Ig-like domains in the extracellular region and a C-terminal conserved motif in the cytoplasmic region (Table 1).

Table 1 C-Terminal Sequences of the Nectin Family

Members	
Nectin-1 $\alpha$	SFISKKEWYV
Nectin-1 $\beta$	VRTTEPRGEC
Nectin-2 $\alpha$	SLISRRAYVY

Table continued

Members	
Nectin-2 $\delta$	DEFVSRAMYV
Nectin-3 $\alpha$	SVISRREWYV
Nectin-3 $\beta$	LYINPREHYV
Nectin-3 $\gamma$	LGQVRALEDT

**[0045]** As in the above, these structural properties of nectin-3 $\alpha$  are similar to those of nectin-1 $\alpha$ , -1 $\beta$ , -2 $\alpha$  and -2 $\delta$ . The extent of homology varied with the regions of the molecules, but the amino acid sequence of the extracellular region of nectin-3 $\alpha$  showed 35.9 % and 30.7 % identities to those of nectin-1 and nectin-2, respectively.

**[0046]** During the isolation of nectin-3 $\alpha$ , two splicing variants (nectin-3 $\beta$  and -3 $\gamma$ ) were isolated. The nectin-3 $\beta$  cDNA (coding region) has a base sequence of 1533 bps (SEQ ID NO: 3), and encodes a protein having an amino acid sequence of 510 amino acids (SEQ ID NO: 4, calculated molecular weight: 55,808). The extracellular region of nectin-3 $\beta$  (1-357 amino acids of SEQ ID NO: 4) is identical to that of nectin-3 $\alpha$ , but its transmembrane and cytoplasmic regions (358-510 amino acids of SEQ ID NO: 4) are different from those of nectin-3 $\alpha$ . However, nectin-3 $\beta$  also has a C-terminal conserved motif (Table 1).

**[0047]** The nectin-3 $\gamma$  cDNA (coding region) has a base sequence of 1317 bps (SEQ ID NO: 5), and encodes a protein having an amino acid sequence of 438 amino acids (SEQ ID NO: 6, calculated molecular weight: 47,259). The extracellular region, transmembrane region and cytoplasmic region of nectin-3 $\gamma$  are identical to those of nectin-3 $\beta$ , but nectin-3 $\gamma$  lacks the C-terminal conserved motif (Table 1).

**[0048]** Fig. 1 is to compare the amino acid sequences (in one-letter coding) of these nectin-3 $\alpha$ , -3 $\beta$  and -3 $\gamma$ .

**[0049]** The following experiments are principally directed to nectin-3 $\alpha$ . This is because the data in Northern blot analysis of various tissues confirm that nectin-3 $\alpha$  is a major splicing variant (see Fig. 8, B1 to B3).

## 2.2 trans Homo-interaction and cis Homo-dimer Formation

**[0050]** Studies with nectin-1 $\alpha$ -L cells and nectin-2 $\alpha$ -L cells confirm that nectin-1 $\alpha$  and nectin-2 $\alpha$  show cell-cell adhesion activity (trans homo-interaction) (J. Cell Biol., 145: 539-549, 1999; J. Biol. Chem., 275: 613-618, 2000). With that, here in examined was whether nectin-3 $\alpha$  also shows the same activity. The polyclonal anti-nectin-3 $\alpha$  antibody recognized two protein bands with molecular masses of about 100 kDa in the expression products by nectin-3 $\alpha$ -L cells (Fig. 2A, Fig. 3). This may be due to the different levels of the post-translational modification such as glycosylation. These molecular masses are different from the calculated molecular weight based on the deduced amino acid sequence. This difference may also be due to the glycosylation. The expression level of nectin-1 $\alpha$ , -2 $\alpha$  and -3 $\alpha$  in each cell line was almost the same (data not shown).

**[0051]** Nectin-3 $\alpha$ -L cells were tested for the cell aggregation activity of nectin-3 $\alpha$ . As a result, the cell aggregation activity of nectin-3 $\alpha$  varied time-dependently (Fig. 2B, C1, C2). EDTA added to nectin-3 $\alpha$  did not have any influence on this activity of nectin-3 $\alpha$  (data not shown). This confirms that the cell-cell adhesion activity of nectin-3 $\alpha$  does not depend on Ca<sup>2+</sup>. These results indicate that nectin-3 $\alpha$  is a Ca<sup>2+</sup>-independent homophilic CAM (cell adhesion molecule), like nectin-1 $\alpha$ , -2 $\alpha$  and -2 $\delta$  (J. Cell Biol., 145: 539-549, 1999; Exp. Cell Res., 235: 374-384, 1997; Blood, 92: 4602-4611, 1998; J. Biol. Chem., 275: 613-618, 2000).

**[0052]** Nectin-1 $\alpha$  and -2 $\alpha$  are known to show cis homo-dimerization (J. Biol. Chem., 275: 613-618, 2000). With that, nectin-3 $\alpha$  was also tested for the same activity. Nectin-3 $\alpha$ -L cells were dissociated to a single-cell suspension and incubated with a cell surface cross-linker, BS3, and then subjected to Western blot analysis using a polyclonal anti-nectin-3 $\alpha$  antibody. The cross-linking of the cell line resulted in the formation of additional bands with molecular masses of about 200 to 220 kDa that correspond to dimers (Fig. 3). Bands with higher molecular masses were also detected. Because the cross-linking was done in a single-cell suspension, it is most likely that the dimers and oligomers are derived from the cis homo-interaction rather than from the trans homo-interaction.

## 2.3 trans Hetero-interaction of Nectin-3 $\alpha$ with Nectin-1 $\alpha$ or -2 $\alpha$

**[0053]** To examine whether each member of the nectin family shows heterophilic cell-cell adhesion activity (trans hetero-interaction), mixed-cell aggregation assay was performed. When Dil-labeled nectin-1 $\alpha$ -L cells were mixed with unlabeled nectin-2 $\alpha$ -L cells, the resulting aggregates exclusively consisted of the labeled cells alone or the unlabeled cells alone (Fig. 4 A1-A3). Few aggregates consisting of both the labeled and unlabeled cells were detected. In contrast, when Dil-labeled nectin-3 $\alpha$ -L cells were mixed with unlabeled nectin-1 $\alpha$ -L cells, the resulting aggregates consisted of

both the labeled cells and the unlabeled cells (Fig. 4, B1-B3). This indicates that nectin-3 $\alpha$  shows trans hetero-interaction with nectin-1 $\alpha$ . The similar result was obtained with nectin-3 $\alpha$  and nectin-2 $\alpha$  (Fig. 4, C1-C3).

[0054] To confirm these results, immunofluorescence microscopy was performed. When nectin-1 $\alpha$ -L cells were co-cultured with nectin-2 $\alpha$ -L cells, nectin-1 $\alpha$  and nectin-2 $\alpha$  were localized in the cell-cell contact sites of the respective L cells (Fig. 5, A1-A3). However, neither nectin-1 $\alpha$  nor nectin-2 $\alpha$  was detected in the contact sites of the two types of the L cells. In contrast, when nectin-3 $\alpha$ -L cells were co-cultured with nectin-1 $\alpha$ -L cells, nectin-3 $\alpha$  and nectin-1 $\alpha$  coexisted in the cell-cell contact site of the two types of the L cells (Fig. 5, B1-B3). The same result was obtained in co-culture of nectin-3 $\alpha$ -L cells and nectin-2 $\alpha$ -L cells (Fig. 5, C1-C3). These results indicate that nectin-3 $\alpha$  shows trans hetero-interaction with nectin-1 $\alpha$  and -2 $\alpha$ , whereas nectin-1 $\alpha$  does not trans hetero-interaction with nectin-2 $\alpha$ .

[0055] To determine whether each member of the nectin family prefers trans homo-interaction or trans hetero-interaction, two-cell aggregates were analyzed through mixed-cell aggregation assay. Consistent with the result in the analysis of two-cell aggregates, the mixture of nectin-1 $\alpha$ -L cells and nectin-2 $\alpha$ -L cells resulted in the formation of homotypic two-cell aggregates (Fig. 6A). In contrast, the mixture of nectin-1 $\alpha$ -L cells and nectin-3 $\alpha$ -L cells resulted in the formation of heterotypic two-cell aggregates, and few homotypic two-cell aggregates were found (Fig. 6B). The similar result was obtained when nectin-3 $\alpha$ -L cells and nectin-2 $\alpha$ -L cells were mixed (Fig. 6C). These results indicate that the affinity of trans hetero-interaction of nectin-3 $\alpha$  with nectin-1 $\alpha$  or -2 $\alpha$  is obviously higher than that of trans homo-interaction of nectin-1 $\alpha$ , -2 $\alpha$  or -3 $\alpha$ .

#### 2.4 cis Hetero-dimerization of Nectin-3 $\alpha$ with Nectin-1 $\alpha$ or -2 $\alpha$

[0056] Next examined was whether nectin-3 $\alpha$  forms a cis hetero-dimer with nectin-1 $\alpha$  or -2 $\alpha$ . Using nectin-1 $\alpha$ /3 $\alpha$ -L cells and nectin-2 $\alpha$ /3 $\alpha$ -L cells, FLAG-nectin-3 $\alpha$  was expressed in the nectin-1 $\alpha$ -L cells and the nectin-2 $\alpha$ -L cells. As a result, the FLAG-nectin-3 $\alpha$  expressed did not change the size of the cis dimers of nectin-1 $\alpha$  or -2 $\alpha$  (Fig. 7, A1 and A2). When nectin-1 $\alpha$ /3 $\alpha$ -L cells were subjected to cell surface cross-linking, followed by immunoprecipitation using the monoclonal anti-FLAG antibody, then nectin-1 $\alpha$  was recovered in the supernatant and was not coimmunoprecipitated with FLAG-nectin-3 $\alpha$  (Fig. 7, B1). The similar result was obtained with nectin-2 $\alpha$ /3 $\alpha$ -L cells (Fig. 7, B2). These results indicate that nectin-3 $\alpha$  does not form a cis hetero-dimer with nectin-1 $\alpha$  or -2 $\alpha$ .

#### 2.5 Tissue Distribution and Intracellular Localization of Nectin-3 $\alpha$

[0057] Consistent with previous reports (J. Virol., 66: 2807-2813, 1992; Gene 155: 261-265, 1995; Gene 159: 267-272, 1995), Northern blot analysis revealed that nectin-1 is abundantly expressed in brain whereas nectin-2 is ubiquitously expressed (Fig. 8, A1 and A2). Northern blot analysis using, as a probe, the coding region common to the three splicing variants of nectin-3 revealed some mRNA bands in various tissues (Fig. 8, A3). To determine the tissue distribution of each splicing variant, a cDNA probe specific to each variant was used. Nectin-3 $\alpha$  gave about 5.2-kb, 3.8-kb, 3.3-kb and 2.7-kb mRNA bands, abundantly expressed in testis but slightly in other tissues (heart, brain, lung, liver and kidney) (Fig. 8, B1). Nectin-3 $\beta$  gave about 5.2-kb and 3.3-kb mRNA bands, expressed in testis (Fig. 8, B2). Nectin-3 $\gamma$  gave an about 3.3-kb mRNA band in testis, and an about 2.1-kb mRNA band in lung, liver and kidney (Fig. 8, B3).

[0058] To determine the intracellular localization of nectin-3 $\alpha$ , immunofluorescence microscopy was performed, using a polyclonal anti-nectin-3 $\alpha$  antibody. Nectin-3 $\alpha$  was colocalized with nectin-2 in the junctional complex regions in mouse small intestine absorptive epithelia (Fig. 9). These results suggest that nectin-3 $\alpha$  is also localized at cadherin-based cell-cell AJs, like nectin-2 (J. Cell Biol., 145: 539-549, 1999).

#### 2.6 Direct Binding of Nectin-3 to Afadin

[0059] To confirm whether nectin-3 $\alpha$  directly binds to afadin, affinity chromatography was performed. The GST-fusion protein in the cytoplasmic region of nectin-3 $\alpha$  (GST-nectin-3 $\alpha$ -CP) bound to the MBP-fusion protein in the PDZ domain of afadin (MBP-afadin-PDZ) immobilized on amylose resin beads (Fig. 10). The stoichiometry of binding of nectin-3 $\alpha$  to afadin was about 1:1. In contrast, the GST-fusion protein in the C-terminal four amino acid residues-deleted cytoplasmic region of nectin-3 $\alpha$  (GST-nectin-3 $\alpha$ -CP- $\Delta$ C) did not bind to the affinity beads. Similarly, the GST-fusion protein in the cytoplasmic region of nectin-3 $\gamma$  that lacks the C-terminal conserved motif did not also bind to the affinity beads.

### INDUSTRIAL APPLICABILITY

[0060] As described in detail hereinabove, the invention of this application provides a novel protein nectin-3 that belongs to one and the same protein family to which nectin-1 and -2 belong. The protein provides important information for clarifying all aspects of the molecular mechanism in cell-cell binding systems, and, in addition, it leads to the possibility of clarifying the mechanism of, for example, humectation and metastasis of carcinoma, and is expected to be applicable

to diagnosis of carcinoma for its malignancy and to a method for treating cases with carcinoma and also to development of medicines for carcinoma.

SEQUENCE LISTING

5

**[0061]**

<110> Japan Science and Technology Corporation

10 <120> Protein Nectine-3

<130> 00-F-039PCT/YS

<140> PCT/JP01/01871

15 <141> 2001-03-09

<150> JP 2000-65595

<151> 2000-03-09

20 <160> 7

<170> PatentIn Ver. 2.1

<210>1

25 <211> 1650

<212> DNA

<213> Mouse

<220>

30 <221> CDS

<222> (1).. (1650)

<300>

<301> Satoh-Horikawa K et al.

35 <302> Nectin-3, a new member of immunoglobulin-like cell adhesion molecules that shows homophilic and heterophilic cell-cell adhesion activities.

<303> J. Biol. Chem.

<304> 275

<305> 14

40 <306> 10291-10299

<307> 2000-04-07

<400> 1

45

50

55

EP 1 179 592 B1

5	atg gcg cgg acc ccg ggc ccg gcc ccg ttg tgt cct gga ggc ggc aaa	48
	Met Ala Arg Thr Pro Gly Pro Ala Pro Leu Cys Pro Gly Gly Gly Lys	
	1                      5                      10                      15	
10	gca caa ctt tcc tcg gcg ttt cct ccc gcg gcc gga ctg ctg ctg ccg	96
	Ala Gln Leu Ser Ser Ala Phe Pro Pro Ala Ala Gly Leu Leu Leu Pro	
	20                      25                      30	
15	gcc ccg acg ccg ccg ccg ctg ctg ctg ctg ctt att ccc ctg ctt ctc	144
	Ala Pro Thr Pro Pro Pro Leu Leu Leu Leu Leu Ile Pro Leu Leu Leu	
	35                      40                      45	
20	ttc tcc cgg ctc tgt ggt gcc tta gct gga tca att att gtg gag cca	192
	Phe Ser Arg Leu Cys Gly Ala Leu Ala Gly Ser Ile Ile Val Glu Pro	
	50                      55                      60	
25	cat gtc aca gca gtg tgg gga aag aat gtt tca ttg aag tgt tta att	240
	His Val Thr Ala Val Trp Gly Lys Asn Val Ser Leu Lys Cys Leu Ile	
	65                      70                      75                      80	
30	gaa gtg aat gaa act ata acc cag atc tca tgg gag aag ata cat ggc	288
	Glu Val Asn Glu Thr Ile Thr Gln Ile Ser Trp Glu Lys Ile His Gly	
	85                      90                      95	
35	aaa agt aca cag act gtt gca gtt cat cat cct cag tat gga ttc tct	336
	Lys Ser Thr Gln Thr Val Ala Val His His Pro Gln Tyr Gly Phe Ser	
	100                      105                      110	
40	gtt caa gga gat tat cag gga aga gtc ttg ttt aaa aac tat tca ctt	384
45		
50		
55		

EP 1 179 592 B1

Val Gln Gly Asp Tyr Gln Gly Arg Val Leu Phe Lys Asn Tyr Ser Leu  
 115 120 125  
 5  
 aat gat gca aca att act ctg cat aac ata ggc ttc tca gat tct gga 432  
 Asn Asp Ala Thr Ile Thr Leu His Asn Ile Gly Phe Ser Asp Ser Gly  
 130 135 140  
 10  
 aaa tat ata tgc aaa gcc gtt aca ttc cca ctt gga aat gct cag tcc 480  
 Lys Tyr Ile Cys Lys Ala Val Thr Phe Pro Leu Gly Asn Ala Gln Ser  
 145 150 155 160  
 15  
 tct aca aca gtg act gtg tta gtt gaa ccc aca gtg agc ctg ata aaa 528  
 Ser Thr Thr Val Thr Val Leu Val Glu Pro Thr Val Ser Leu Ile Lys  
 165 170 175  
 20  
 ggg ccg gat tct tta att gat gga ggg aat gag aca gta gca gcc gtt 576  
 Gly Pro Asp Ser Leu Ile Asp Gly Gly Asn Glu Thr Val Ala Ala Val  
 180 185 190  
 25  
 tgt gta gca gcc act gga aag cca gtc gca cag att gac tgg gaa ggt 624  
 Cys Val Ala Ala Thr Gly Lys Pro Val Ala Gln Ile Asp Trp Glu Gly  
 195 200 205  
 30  
 gat ctt ggt gaa atg gaa tct agt aca act tct ttt cct aat gaa aca 672  
 Asp Leu Gly Glu Met Glu Ser Ser Thr Thr Ser Phe Pro Asn Glu Thr  
 210 215 220  
 35  
 gca acg att gtc agc caa tac aag ctg ttt ccc aca aga ttt gct cga 720  
 Ala Thr Ile Val Ser Gln Tyr Lys Leu Phe Pro Thr Arg Phe Ala Arg  
 225 230 235 240  
 40  
 gga agg cga att act tgt gtt gta aaa cat cca gcc tta gaa aag gac 768  
 Gly Arg Arg Ile Thr Cys Val Val Lys His Pro Ala Leu Glu Lys Asp  
 45  
 50  
 55

		245		250		255		
5	att cgc tac tct ttc ata cta gac ata cag tat gct cct gaa gtt tca							816
	Ile Arg Tyr Ser Phe Ile Leu Asp Ile Gln Tyr Ala Pro Glu Val Ser							
		260		265		270		
10								
	gta aca gga tat gat gga aat tgg ttc gtg gga aga aaa ggt gtt aac							864
	Val Thr Gly Tyr Asp Gly Asn Trp Phe Val Gly Arg Lys Gly Val Asn							
15		275		280		285		
	ctc aag tgt aat gct gat gca aac cct cca ccc ttc aag tcc gtg tgg							912
20	Leu Lys Cys Asn Ala Asp Ala Asn Pro Pro Pro Phe Lys Ser Val Trp							
		290		295		300		
	agc agg ttg gat gga caa tgg cct gat ggt tta ttg gcg tca gat aat							960
25	Ser Arg Leu Asp Gly Gln Trp Pro Asp Gly Leu Leu Ala Ser Asp Asn							
		305		310		315		320
30								
	act ctt cat ttt gtc cat cca ttg act gtc aat tat tct ggc gtt tat							1008
	Thr Leu His Phe Val His Pro Leu Thr Val Asn Tyr Ser Gly Val Tyr							
35		325		330		335		
	gtc tgt aaa gta tca aat tcc ctt ggt caa aga agt gat caa aag gtt							1056
40	Val Cys Lys Val Ser Asn Ser Leu Gly Gln Arg Ser Asp Gln Lys Val							
		340		345		350		
	atc tac att tca gat cct cct acc acc acc acc ctt cag ccg aca gtt							1104
45	Ile Tyr Ile Ser Asp Pro Pro Thr Thr Thr Thr Leu Gln Pro Thr Val							
		355		360		365		
50								
	cag tgg cat tcc tca cct gct gac gtc cag gat ata gca aca gag cat							1152
	Gln Trp His Ser Ser Pro Ala Asp Val Gln Asp Ile Ala Thr Glu His							
55		370		375		380		



5 gat cta aaa atg gga atg aag ttt gtc agt gat gaa cgc tac aat gaa 1584  
 Asp Leu Lys Met Gly Met Lys Phe Val Ser Asp Glu Arg Tyr Asn Glu  
 515 520 525

10 agt gaa gat ggt ttg gtt tct cat gta gat ggc tcc gta att tcc agg 1632  
 Ser Glu Asp Gly Leu Val Ser His Val Asp Gly Ser Val Ile Ser Arg  
 530 535 540

15 agg gag tgg tat gtc taa 1650  
 Arg Glu Trp Tyr Val  
 20 545 550

25 <210> 2  
 <211> 549  
 <212> PRT  
 <213> Mouse

<400> 2

30 Met Ala Arg Thr Pro Gly Pro Ala Pro Leu Cys Pro Gly Gly Gly Lys  
 1 5 10 15  
 Ala Gln Leu Ser Ser Ala Phe Pro Pro Ala Ala Gly Leu Leu Leu Pro  
 35 20 25 30  
 Ala Pro Thr Pro Pro Pro Leu Leu Leu Leu Ile Pro Leu Leu Leu  
 35 40 45  
 40 Phe Ser Arg Leu Cys Gly Ala Leu Ala Gly Ser Ile Ile Val Glu Pro  
 50 55 60  
 His Val Thr Ala Val Trp Gly Lys Asn Val Ser Leu Lys Cys Leu Ile  
 45 65 70 75 80  
 Glu Val Asn Glu Thr Ile Thr Gln Ile Ser Trp Glu Lys Ile His Gly  
 85 90 95  
 50 Lys Ser Thr Gln Thr Val Ala Val His His Pro Gln Tyr Gly Phe Ser  
 100 105 110

55

Val Gln Gly Asp Tyr Gln Gly Arg Val Leu Phe Lys Asn Tyr Ser Leu  
 115 120 125  
 5 Asn Asp Ala Thr Ile Thr Leu His Asn Ile Gly Phe Ser Asp Ser Gly  
 130 135 140  
 Lys Tyr Ile Cys Lys Ala Val Thr Phe Pro Leu Gly Asn Ala Gln Ser  
 10 145 150 155 160  
 Ser Thr Thr Val Thr Val Leu Val Glu Pro Thr Val Ser Leu Ile Lys  
 165 170 175  
 15 Gly Pro Asp Ser Leu Ile Asp Gly Gly Asn Glu Thr Val Ala Ala Val  
 180 185 190  
 Cys Val Ala Ala Thr Gly Lys Pro Val Ala Gln Ile Asp Trp Glu Gly  
 20 195 200 205  
 Asp Leu Gly Glu Met Glu Ser Ser Thr Thr Ser Phe Pro Asn Glu Thr  
 210 215 220  
 25 Ala Thr Ile Val Ser Gln Tyr Lys Leu Phe Pro Thr Arg Phe Ala Arg  
 225 230 235 240  
 Gly Arg Arg Ile Thr Cys Val Val Lys His Pro Ala Leu Glu Lys Asp  
 30 245 250 255  
 Ile Arg Tyr Ser Phe Ile Leu Asp Ile Gln Tyr Ala Pro Glu Val Ser  
 260 265 270  
 35 Val Thr Gly Tyr Asp Gly Asn Trp Phe Val Gly Arg Lys Gly Val Asn  
 275 280 285  
 Leu Lys Cys Asn Ala Asp Ala Asn Pro Pro Pro Phe Lys Ser Val Trp  
 40 290 295 300  
 Ser Arg Leu Asp Gly Gln Trp Pro Asp Gly Leu Leu Ala Ser Asp Asn  
 305 310 315 320  
 45 Thr Leu His Phe Val His Pro Leu Thr Val Asn Tyr Ser Gly Val Tyr  
 325 330 335  
 Val Cys Lys Val Ser Asn Ser Leu Gly Gln Arg Ser Asp Gln Lys Val  
 340 345 350  
 50 Ile Tyr Ile Ser Asp Pro Pro Thr Thr Thr Thr Leu Gln Pro Thr Val  
 355 360 365  
 55 Gln Trp His Ser Ser Pro Ala Asp Val Gln Asp Ile Ala Thr Glu His

5                   370                               375                               380  
 Lys Lys Leu Pro Phe Pro Leu Ser Thr Leu Ala Thr Leu Lys Asp Asp  
 385   390                               395                               400  
 Thr Ile Gly Thr Ile Ile Ala Ser Val Val Gly Gly Ala Leu Phe Leu  
 10   405                               410                               415  
 Val Leu Val Ser Ile Leu Ala Gly Val Phe Cys Tyr Arg Arg Arg Arg  
 15   420                               425                               430  
 Thr Phe Arg Gly Asp Tyr Phe Ala Lys Asn Tyr Ile Pro Pro Ser Asp  
 20   435                               440                               445  
 Met Gln Lys Glu Ser Gln Ile Asp Val Leu His Gln Asp Glu Leu Asp  
 25   450                               455                               460  
 Ser Tyr Pro Asp Ser Val Lys Lys Glu Asn Lys Asn Pro Val Asn Asn  
 30   465                               470                               475                               480  
 Leu Ile Arg Lys Asp Tyr Leu Glu Glu Pro Glu Lys Thr Gln Trp Asn  
 35   485                               490                               495  
 Asn Val Glu Asn Leu Thr Arg Phe Glu Arg Pro Met Asp Tyr Tyr Glu  
 40   500                               505                               510  
 Asp Leu Lys Met Gly Met Lys Phe Val Ser Asp Glu Arg Tyr Asn Glu  
 45   515                               520                               525  
 Ser Glu Asp Gly Leu Val Ser His Val Asp Gly Ser Val Ile Ser Arg  
 50   530                               535                               540  
 Arg Glu Trp Tyr Val  
 55   545

<210> 3

<211> 1533

<212> DNA

<213> Mouse

<220>

<221> CDS

<222> (1).. (1533)

<300>

<301> Satoh-Horikawa K et al.

<302> Nectin-3, a new member of immunoglobulin-like cell adhesion molecules that shows homophilic and heterophilic cell-cell adhesion activities.

<303> J. Biol. Chem.

<304> 275

<305> 14

<306> 10291-10299

<307> 2000-04-07

EP 1 179 592 B1

<308> GenBank accession No. AF195834

<309> 2000-04-13

<400> 3

5  
atg gcg cgg acc ccg ggc ccg gcc ccg ttg tgt cct gga ggc ggc aaa 48  
Met Ala Arg Thr Pro Gly Pro Ala Pro Leu Cys Pro Gly Gly Gly Lys  
10 1 5 10 15  
gca caa ctt tcc tcg gcg ttt cct ccc gcg gcc gga ctg ctg ctg ccg 96  
15 Ala Gln Leu Ser Ser Ala Phe Pro Pro Ala Ala Gly Leu Leu Leu Pro  
20 20 25 30  
gcc ccg acg ccg ccg ccg ctg ctg ctg ctg ctt att ccc ctg ctt ctc 144  
20 Ala Pro Thr Pro Pro Pro Leu Leu Leu Leu Leu Ile Pro Leu Leu Leu  
35 40 45  
ttc tcc cgg ctc tgt ggt gcc tta gct gga tca att att gtg gag cca 192  
25 Phe Ser Arg Leu Cys Gly Ala Leu Ala Gly Ser Ile Ile Val Glu Pro  
30 50 55 60  
cat gtc aca gca gtg tgg gga aag aat gtt tca ttg aag tgt tta att 240  
35 His Val Thr Ala Val Trp Gly Lys Asn Val Ser Leu Lys Cys Leu Ile  
40  
45  
50  
55

EP 1 179 592 B1

	65		70		75		80	
5	gaa gtg aat gaa act ata acc cag atc tca tgg gag aag ata cat ggc							288
	Glu Val Asn Glu Thr Ile Thr Gln Ile Ser Trp Glu Lys Ile His Gly							
			85		90		95	
10	aaa agt aca cag act gtt gca gtt cat cat cct cag tat gga ttc tct							336
	Lys Ser Thr Gln Thr Val Ala Val His His Pro Gln Tyr Gly Phe Ser							
15			100		105		110	
20	gtt caa gga gat tat cag gga aga gtc ttg ttt aaa aac tat tca ctt							384
	Val Gln Gly Asp Tyr Gln Gly Arg Val Leu Phe Lys Asn Tyr Ser Leu							
			115		120		125	
25	aat gat gca aca att act ctg cat aac ata ggc ttc tca gat tct gga							432
	Asn Asp Ala Thr Ile Thr Leu His Asn Ile Gly Phe Ser Asp Ser Gly							
			130		135		140	
30	aaa tat ata tgc aaa gcc gtt aca ttc cca ctt gga aat gct cag tcc							480
	Lys Tyr Ile Cys Lys Ala Val Thr Phe Pro Leu Gly Asn Ala Gln Ser							
35			145		150		155	
40	tct aca aca gtg act gtg tta gtt gaa ccc aca gtg agc ctg ata aaa							528
	Ser Thr Thr Val Thr Val Leu Val Glu Pro Thr Val Ser Leu Ile Lys							
			165		170		175	
45	ggg ccg gat tct tta att gat gga ggg aat gag aca gta gca gcc gtt							576
	Gly Pro Asp Ser Leu Ile Asp Gly Gly Asn Glu Thr Val Ala Ala Val							
			180		185		190	
50	tgt gta gca gcc act gga aag cca gtc gca cag att gac tgg gaa ggt							624
	Cys Val Ala Ala Thr Gly Lys Pro Val Ala Gln Ile Asp Trp Glu Gly							
55			195		200		205	

EP 1 179 592 B1

5           gat ctt ggt gaa atg gaa tct agt aca act tct ttt cct aat gaa aca   672  
           Asp Leu Gly Glu Met Glu Ser Ser Thr Thr Ser Phe Pro Asn Glu Thr  
           210                           215                           220

10           gca acg att gtc agc caa tac aag ctg ttt ccc aca aga ttt gct cga   720  
           Ala Thr Ile Val Ser Gln Tyr Lys Leu Phe Pro Thr Arg Phe Ala Arg  
           225                           230                           235                           240

15           gga agg cga att act tgt gtt gta aaa cat cca gcc tta gaa aag gac   768  
           Gly Arg Arg Ile Thr Cys Val Val Lys His Pro Ala Leu Glu Lys Asp  
                                   245                           250                           255

20           att cgc tac tct ttc ata cta gac ata cag tat gct cct gaa gtt tca   816  
           Ile Arg Tyr Ser Phe Ile Leu Asp Ile Gln Tyr Ala Pro Glu Val Ser  
                                   260                           265                           270

25           gta aca gga tat gat gga aat tgg ttc gtg gga aga aaa ggt gtt aac   864  
           Val Thr Gly Tyr Asp Gly Asn Trp Phe Val Gly Arg Lys Gly Val Asn  
                                   275                           280                           285

30           ctc aag tgt aat gct gat gca aac cct cca ccc ttc aag tcc gtg tgg   912  
           Leu Lys Cys Asn Ala Asp Ala Asn Pro Pro Pro Phe Lys Ser Val Trp  
                                   290                           295                           300

35           agc agg ttg gat gga caa tgg cct gat ggt tta ttg gcg tca gat aat   960  
           Ser Arg Leu Asp Gly Gln Trp Pro Asp Gly Leu Leu Ala Ser Asp Asn  
           305                           310                           315                           320

40           act ctt cat ttt gtc cat cca ttg act gtc aat tat tct ggc gtt tat   1008  
           Thr Leu His Phe Val His Pro Leu Thr Val Asn Tyr Ser Gly Val Tyr  
                                   325                           330                           335

45  
 50  
 55



5  
 Glu Ser Thr Met Gln Glu Asp Gly Thr Gln Arg Met Cys Pro Leu Tyr  
 465 470 475 480

10  
 agc cag atg tgc cac caa gac cga agc cct cgc caa cat cac cca cgc 1488  
 Ser Gln Met Cys His Gln Asp Arg Ser Pro Arg Gln His His Pro Arg  
 485 490 495

15  
 aac ccc gag aga ctc tac atc aac cca cga gaa cat tat gtg tga 1533  
 Asn Pro Glu Arg Leu Tyr Ile Asn Pro Arg Glu His Tyr Val  
 500 505 510

20  
 <210> 4  
 <211> 510  
 <212> PRT  
 <213> Mouse

25  
 <400> 4

30  
 Met Ala Arg Thr Pro Gly Pro Ala Pro Leu Cys Pro Gly Gly Gly Lys  
 1 5 10 15  
 Ala Gln Leu Ser Ser Ala Phe Pro Pro Ala Ala Gly Leu Leu Leu Pro  
 20 25 30

35  
 Ala Pro Thr Pro Pro Pro Leu Leu Leu Leu Ile Pro Leu Leu Leu  
 35 40 45  
 Phe Ser Arg Leu Cys Gly Ala Leu Ala Gly Ser Ile Ile Val Glu Pro  
 40 50 55 60  
 His Val Thr Ala Val Trp Gly Lys Asn Val Ser Leu Lys Cys Leu Ile  
 65 70 75 80

45  
 Glu Val Asn Glu Thr Ile Thr Gln Ile Ser Trp Glu Lys Ile His Gly  
 85 90 95  
 Lys Ser Thr Gln Thr Val Ala Val His His Pro Gln Tyr Gly Phe Ser  
 100 105 110  
 Val Gln Gly Asp Tyr Gln Gly Arg Val Leu Phe Lys Asn Tyr Ser Leu

	115	120	125
5	Asn Asp Ala Thr Ile Thr Leu His Asn Ile Gly Phe Ser Asp Ser Gly		
	130	135	140
10	Lys Tyr Ile Cys Lys Ala Val Thr Phe Pro Leu Gly Asn Ala Gln Ser		
	145	150	155
	Ser Thr Thr Val Thr Val Leu Val Glu Pro Thr Val Ser Leu Ile Lys		
	165	170	175
15	Gly Pro Asp Ser Leu Ile Asp Gly Gly Asn Glu Thr Val Ala Ala Val		
	180	185	190
	Cys Val Ala Ala Thr Gly Lys Pro Val Ala Gln Ile Asp Trp Glu Gly		
20	195	200	205
	Asp Leu Gly Glu Met Glu Ser Ser Thr Thr Ser Phe Pro Asn Glu Thr		
	210	215	220
25	Ala Thr Ile Val Ser Gln Tyr Lys Leu Phe Pro Thr Arg Phe Ala Arg		
	225	230	235
	Gly Arg Arg Ile Thr Cys Val Val Lys His Pro Ala Leu Glu Lys Asp		
	245	250	255
30	Ile Arg Tyr Ser Phe Ile Leu Asp Ile Gln Tyr Ala Pro Glu Val Ser		
	260	265	270
	Val Thr Gly Tyr Asp Gly Asn Trp Phe Val Gly Arg Lys Gly Val Asn		
35	275	280	285
	Leu Lys Cys Asn Ala Asp Ala Asn Pro Pro Pro Phe Lys Ser Val Trp		
	290	295	300
40	Ser Arg Leu Asp Gly Gln Trp Pro Asp Gly Leu Leu Ala Ser Asp Asn		
	305	310	315
	Thr Leu His Phe Val His Pro Leu Thr Val Asn Tyr Ser Gly Val Tyr		
45	325	330	335
	Val Cys Lys Val Ser Asn Ser Leu Gly Gln Arg Ser Asp Gln Lys Val		
	340	345	350
50	Ile Tyr Ile Ser Asp Ile Pro Leu Thr Gln Thr Ser Ser Ile Ala Val		
	355	360	365
	Ala Gly Ala Val Ile Gly Ala Val Leu Ala Leu Phe Ile Ile Thr Val		
55	370	375	380





EP 1 179 592 B1

5 Lys Ser Thr Gln Thr Val Ala Val His His Pro Gln Tyr Gly Phe Ser  
 100 105 110  
 gtt caa gga gat tat cag gga aga gtc ttg ttt aaa aac tat tca ctt 384  
 10 Val Gln Gly Asp Tyr Gln Gly Arg Val Leu Phe Lys Asn Tyr Ser Leu  
 115 120 125  
 aat gat gca aca att act ctg cat aac ata ggc ttc tca gat tct gga 432  
 15 Asn Asp Ala Thr Ile Thr Leu His Asn Ile Gly Phe Ser Asp Ser Gly  
 130 135 140  
 aaa tat ata tgc aaa gcc gtt aca ttc cca ctt gga aat gct cag tcc 480  
 20 Lys Tyr Ile Cys Lys Ala Val Thr Phe Pro Leu Gly Asn Ala Gln Ser  
 145 150 155 160  
 25 tct aca aca gtg act gtg tta gtt gaa ccc aca gtg agc ctg ata aaa 528  
 Ser Thr Thr Val Thr Val Leu Val Glu Pro Thr Val Ser Leu Ile Lys  
 30 165 170 175  
 ggg ccg gat tct tta att gat gga ggg aat gag aca gta gca gcc gtt 576  
 35 Gly Pro Asp Ser Leu Ile Asp Gly Gly Asn Glu Thr Val Ala Ala Val  
 180 185 190  
 tgt gta gca gcc act gga aag cca gtc gca cag att gac tgg gaa ggt 624  
 40 Cys Val Ala Ala Thr Gly Lys Pro Val Ala Gln Ile Asp Trp Glu Gly  
 195 200 205  
 45 gat ctt ggt gaa atg gaa tct agt aca act tct ttt cct aat gaa aca 672  
 Asp Leu Gly Glu Met Glu Ser Ser Thr Thr Ser Phe Pro Asn Glu Thr  
 50 210 215 220  
 gca acg att gtc agc caa tac aag ctg ttt ccc aca aga ttt gct cga 720  
 55 Ala Thr Ile Val Ser Gln Tyr Lys Leu Phe Pro Thr Arg Phe Ala Arg

EP 1 179 592 B1

	225		230		235		240	
5	gga agg cga att act tgt gtt gta aaa cat cca gcc tta gaa aag gac							768
	Gly Arg Arg Ile Thr Cys Val Val Lys His Pro Ala Leu Glu Lys Asp							
			245		250		255	
10								
	att cgc tac tct ttc ata cta gac ata cag tat gct cct gaa gtt tca							816
	Ile Arg Tyr Ser Phe Ile Leu Asp Ile Gln Tyr Ala Pro Glu Val Ser							
15			260		265		270	
	gta aca gga tat gat gga aat tgg ttc gtg gga aga aaa ggt gtt aac							864
20	Val Thr Gly Tyr Asp Gly Asn Trp Phe Val Gly Arg Lys Gly Val Asn							
			275		280		285	
	ctc aag tgt aat gct gat gca aac cct cca ccc ttc aag tcc gtg tgg							912
	Leu Lys Cys Asn Ala Asp Ala Asn Pro Pro Pro Phe Lys Ser Val Trp							
25			290		295		300	
	agc agg ttg gat gga caa tgg cct gat ggt tta ttg gcg tca gat aat							960
	Ser Arg Leu Asp Gly Gln Trp Pro Asp Gly Leu Leu Ala Ser Asp Asn							
30			305		310		315	320
	act ctt cat ttt gtc cat cca ttg act gtc aat tat tct ggc gtt tat							1008
35	Thr Leu His Phe Val His Pro Leu Thr Val Asn Tyr Ser Gly Val Tyr							
			325		330		335	
	gtc tgt aaa gta tca aat tcc ctt ggt caa aga agt gat caa aag gtt							1056
40	Val Cys Lys Val Ser Asn Ser Leu Gly Gln Arg Ser Asp Gln Lys Val							
			340		345		350	
	atc tac att tca gac atc ccg ctt acg cag acc tca tcc ata gca gtg							1104
45	Ile Tyr Ile Ser Asp Ile Pro Leu Thr Gln Thr Ser Ser Ile Ala Val							
			355		360		365	
50								
55								

EP 1 179 592 B1

5           gct gga gcc gtg att gga gct gtc ctg gcc ctc ttc atc atc acc gtc   1152  
           Ala Gly Ala Val Ile Gly Ala Val Leu Ala Leu Phe Ile Ile Thr Val  
           370                   375                   380

10          ttt gtg act gtg ttg ctg acg cct cgg aaa aag aga ccg tcc tat ctt   1200  
           Phe Val Thr Val Leu Leu Thr Pro Arg Lys Lys Arg Pro Ser Tyr Leu  
           385                   390                   395                   400

15          gac aaa gta atc gac ctt cca cct aca cat aag cca ccc cct gta tat   1248  
           Asp Lys Val Ile Asp Leu Pro Pro Thr His Lys Pro Pro Pro Val Tyr  
                           405                   410                   415

20          gaa gaa cga att cct tct ctc cct cag aaa gac ctt ctt ggc cag gta   1296  
           Glu Glu Arg Ile Pro Ser Leu Pro Gln Lys Asp Leu Leu Gly Gln Val  
                           420                   425                   430

30          cgt gct ctc gaa gac act taa                                   1317  
           Arg Ala Leu Glu Asp Thr  
                           435

35          <210> 6  
           <211> 438  
           <212> PRT  
           <213> Mouse  
  
           <400> 6

40                   Met Ala Arg Thr Pro Gly Pro Ala Pro Leu Cys Pro Gly Gly Gly Lys  
                           1                   5                   10                   15  
 45                   Ala Gln Leu Ser Ser Ala Phe Pro Pro Ala Ala Gly Leu Leu Leu Pro  
                           20                   25                   30  
 50                   Ala Pro Thr Pro Pro Pro Leu Leu Leu Leu Leu Ile Pro Leu Leu Leu

55

		35				40				45						
5	Phe	Ser	Arg	Leu	Cys	Gly	Ala	Leu	Ala	Gly	Ser	Ile	Ile	Val	Glu	Pro
		50				55				60						
	His	Val	Thr	Ala	Val	Trp	Gly	Lys	Asn	Val	Ser	Leu	Lys	Cys	Leu	Ile
10	65					70				75					80	
	Glu	Val	Asn	Glu	Thr	Ile	Thr	Gln	Ile	Ser	Trp	Glu	Lys	Ile	His	Gly
					85					90					95	
15	Lys	Ser	Thr	Gln	Thr	Val	Ala	Val	His	His	Pro	Gln	Tyr	Gly	Phe	Ser
					100					105					110	
	Val	Gln	Gly	Asp	Tyr	Gln	Gly	Arg	Val	Leu	Phe	Lys	Asn	Tyr	Ser	Leu
20					115					120					125	
	Asn	Asp	Ala	Thr	Ile	Thr	Leu	His	Asn	Ile	Gly	Phe	Ser	Asp	Ser	Gly
	130					135									140	
25	Lys	Tyr	Ile	Cys	Lys	Ala	Val	Thr	Phe	Pro	Leu	Gly	Asn	Ala	Gln	Ser
	145					150									155	
	Ser	Thr	Thr	Val	Thr	Val	Leu	Val	Glu	Pro	Thr	Val	Ser	Leu	Ile	Lys
						165									170	
30	Gly	Pro	Asp	Ser	Leu	Ile	Asp	Gly	Gly	Asn	Glu	Thr	Val	Ala	Ala	Val
						180									185	
	Cys	Val	Ala	Ala	Thr	Gly	Lys	Pro	Val	Ala	Gln	Ile	Asp	Trp	Glu	Gly
35						195									200	
	Asp	Leu	Gly	Glu	Met	Glu	Ser	Ser	Thr	Thr	Ser	Phe	Pro	Asn	Glu	Thr
	210														215	
40	Ala	Thr	Ile	Val	Ser	Gln	Tyr	Lys	Leu	Phe	Pro	Thr	Arg	Phe	Ala	Arg
	225														230	
	Gly	Arg	Arg	Ile	Thr	Cys	Val	Val	Lys	His	Pro	Ala	Leu	Glu	Lys	Asp
45															245	
	Ile	Arg	Tyr	Ser	Phe	Ile	Leu	Asp	Ile	Gln	Tyr	Ala	Pro	Glu	Val	Ser
															250	
															260	
50	Val	Thr	Gly	Tyr	Asp	Gly	Asn	Trp	Phe	Val	Gly	Arg	Lys	Gly	Val	Asn
															265	
															270	
															275	
															280	
															285	
55	Leu	Lys	Cys	Asn	Ala	Asp	Ala	Asn	Pro	Pro	Pro	Phe	Lys	Ser	Val	Trp
	290														295	
															300	



EP 1 179 592 B1

gaattcggca cgagcgacgg cggagtcgag gcagccgca gcgctcggcc gagtggcggc 60

5 gggcggcgac ggcgcaggag ccgggggttg aggacacgcg cgctggccct tccgcggcg 120

ggccggccgc gccggccca cccagagcct gaggcgccgg ggcgcggcg agcgggtggg 180

10 ccggggcaag gcgggc atg gcg cgg acc ccg ggc ccg gcc cgg ttg tgt cct 232

Met Ala Arg Thr Pro Gly Pro Ala Pro Leu Cys Pro

15 1 5 10

gga ggc ggc aaa gca caa ctt tcc tcg gcg ttt cct ccc gcg gcc gga 280

Gly Gly Gly Lys Ala Gln Leu Ser Ser Ala Phe Pro Pro Ala Ala Gly

20 15 20 25

ctg ctg ctg ccg gcc ccg acg ccg ccg ccg ctg ctg ctg ctg ctt att 328

Leu Leu Leu Pro Ala Pro Thr Pro Pro Pro Leu Leu Leu Leu Ile

25 30 35 40

ccc ctg ctt ctc ttc tcc cgg ctc tgt ggt gcc tta gct gga tca att 376

Pro Leu Leu Leu Phe Ser Arg Leu Cys Gly Ala Leu Ala Gly Ser Ile

35 45 50 55 60

att gtg gag cca cat gtc aca gca gtg tgg gga aag aat gtt tca ttg 424

40

45

50

55

Ile Val Glu Pro His Val Thr Ala Val Trp Gly Lys Asn Val Ser Leu  
 65 70 75  
 5  
 aag tgt tta att gaa gtg aat gaa act ata acc cag atc tca tgg gag 472  
 Lys Cys Leu Ile Glu Val Asn Glu Thr Ile Thr Gln Ile Ser Trp Glu  
 10 80 85 90  
 aag ata cat ggc aaa agt aca cag act gtt gca gtt cat cat cct cag 520  
 15 Lys Ile His Gly Lys Ser Thr Gln Thr Val Ala Val His His Pro Gln  
 95 100 105  
 tat gga ttc tct gtt caa gga gat tat cag gga aga gtc ttg ttt aaa 568  
 20 Tyr Gly Phe Ser Val Gln Gly Asp Tyr Gln Gly Arg Val Leu Phe Lys  
 110 115 120  
 25  
 aac tat tca ctt aat gat gca aca att act ctg cat aac ata ggc ttc 616  
 30 Asn Tyr Ser Leu Asn Asp Ala Thr Ile Thr Leu His Asn Ile Gly Phe  
 125 130 135 140  
 tca gat tct gga aaa tat ata tgc aaa gcc gtt aca ttc cca ctt gga 664  
 35 Ser Asp Ser Gly Lys Tyr Ile Cys Lys Ala Val Thr Phe Pro Leu Gly  
 145 150 155  
 aat gct cag tcc tct aca aca gtg act gtg tta gtt gaa ccc aca gtg 712  
 40 Asn Ala Gln Ser Ser Thr Thr Val Thr Val Leu Val Glu Pro Thr Val  
 160 165 170  
 45  
 agc ctg ata aaa ggg ccg gat tct tta att gat gga ggg aat gag aca 760  
 Ser Leu Ile Lys Gly Pro Asp Ser Leu Ile Asp Gly Gly Asn Glu Thr  
 175 180 185  
 50  
 gta gca gcc gtt tgt gta gca gcc act gga aag cca gtc gca cag att 808  
 55 Val Ala Ala Val Cys Val Ala Ala Thr Gly Lys Pro Val Ala Gln Ile

EP 1 179 592 B1

	190		195		200	
5	gac tgg gaa ggt gat ctt ggt gaa atg gaa tct agt aca act tct ttt					856
	Asp Trp Glu Gly Asp Leu Gly Glu Met Glu Ser Ser Thr Thr Ser Phe					
10	205		210		215	220
	cct aat gaa aca gca acg att gtc agc caa tac aag ctg ttt ccc aca					904
15	Pro Asn Glu Thr Ala Thr Ile Val Ser Gln Tyr Lys Leu Phe Pro Thr					
		225		230		235
	aga ttt gct cga gga agg cga att act tgt gtt gta aaa cat cca gcc					952
20	Arg Phe Ala Arg Gly Arg Arg Ile Thr Cys Val Val Lys His Pro Ala					
		240		245		250
25	tta gaa aag gac att cgc tac tct ttc ata cta gac ata cag tat gct					1000
	Leu Glu Lys Asp Ile Arg Tyr Ser Phe Ile Leu Asp Ile Gln Tyr Ala					
		255		260		265
30	cct gaa gtt tca gta aca gga tat gat gga aat tgg ttc gtg gga aga					1048
	Pro Glu Val Ser Val Thr Gly Tyr Asp Gly Asn Trp Phe Val Gly Arg					
35	270		275		280	
	aaa ggt gtt aac ctc aag tgt aat gct gat gca aac cct cca ccc ttc					1096
40	Lys Gly Val Asn Leu Lys Cys Asn Ala Asp Ala Asn Pro Pro Pro Phe					
	285		290		295	300
	aag tcc gtg tgg agc agg ttg gat gga caa tgg cct gat ggt tta ttg					1144
45	Lys Ser Val Trp Ser Arg Leu Asp Gly Gln Trp Pro Asp Gly Leu Leu					
		305		310		315
50	gcg tca gat aat act ctt cat ttt gtc cat cca ttg act gtc aat tat					1192
	Ala Ser Asp Asn Thr Leu His Phe Val His Pro Leu Thr Val Asn Tyr					
55		320		325		330

EP 1 179 592 B1

5 tct ggc gtt tat gtc tgt aaa gta tca aat tcc ctt ggt caa aga agt 1240  
 Ser Gly Val Tyr Val Cys Lys Val Ser Asn Ser Leu Gly Gln Arg Ser  
 335 340 345

10 gat caa aag gtt atc tac att tca gat cct cct acc acc acc acc ctt 1288  
 Asp Gln Lys Val Ile Tyr Ile Ser Asp Pro Pro Thr Thr Thr Thr Leu  
 350 355 360

15 cag ccg aca gtt cag tgg cat tcc tca cct gct gac gtc cag gat ata 1336  
 Gln Pro Thr Val Gln Trp His Ser Ser Pro Ala Asp Val Gln Asp Ile  
 20 365 370 375 380

25 gca aca gag cat aaa aaa ttg ccc ttt cct ttg tca act ttg gca aca 1384  
 Ala Thr Glu His Lys Lys Leu Pro Phe Pro Leu Ser Thr Leu Ala Thr  
 385 390 395

30 ctt aag gat gac aca att ggc acc atc att gct agt gta gtg ggt ggg 1432  
 Leu Lys Asp Asp Thr Ile Gly Thr Ile Ile Ala Ser Val Val Gly Gly  
 400 405 410

35 gct ctc ttc tta gtg ctt gtg agc att tta gct ggg gta ttc tgc tat 1480  
 Ala Leu Phe Leu Val Leu Val Ser Ile Leu Ala Gly Val Phe Cys Tyr  
 415 420 425

40 agg aga cga cgg acg ttt cgt gga gac tac ttt gcc aaa aac tac att 1528  
 Arg Arg Arg Arg Thr Phe Arg Gly Asp Tyr Phe Ala Lys Asn Tyr Ile  
 45 430 435 440

50 cca cca tca gac atg cag aaa gaa tca cag att gat gtt ctt cac cag 1576  
 Pro Pro Ser Asp Met Gln Lys Glu Ser Gln Ile Asp Val Leu His Gln  
 445 450 455 460

55

EP 1 179 592 B1

5 gat gag ctg gat tct tac cca gac agt gta aaa aag gaa aac aaa aat 1624  
 Asp Glu Leu Asp Ser Tyr Pro Asp Ser Val Lys Lys Glu Asn Lys Asn  
 465 470 475

10 cca gta aac aac ctg atc cgc aaa gac tac tta gag gag cct gag aaa 1672  
 Pro Val Asn Asn Leu Ile Arg Lys Asp Tyr Leu Glu Glu Pro Glu Lys  
 480 485 490

15 act cag tgg aat aat gta gag aac ctc act agg ttt gaa aga ccg atg 1720  
 Thr Gln Trp Asn Asn Val Glu Asn Leu Thr Arg Phe Glu Arg Pro Met  
 495 500 505

20 gat tac tat gaa gat cta aaa atg gga atg aag ttt gtc agt gat gaa 1768  
 Asp Tyr Tyr Glu Asp Leu Lys Met Gly Met Lys Phe Val Ser Asp Glu  
 510 515 520

25 cgc tac aat gaa agt gaa gat ggt ttg gtt tct cat gta gat ggc tcc 1816  
 Arg Tyr Asn Glu Ser Glu Asp Gly Leu Val Ser His Val Asp Gly Ser  
 525 530 535 540

30 gta att tcc agg agg gag tgg tat gtc taa cagccactga cgcgacttca 1866  
 Val Ile Ser Arg Arg Glu Trp Tyr Val  
 545 550

35 ctatgtacaa ggtttcattc aactagttg accattttca gattgttcat actttttctt 1926

40 gaggaagaat aagctttttc aagttgattt cgagcttact ttttatattc tgatctgaca 1986

45 aatgaaaatg taaaacctgg gttcaatgta tctgagctgc tttacagttt tcaactgctat 2046

50 actactgtct caagatttaa attctaatgc agagtacttt attggtctga ggcacacagg 2106

55 taagaaagat gtcaacgta aatgtaatgac gtttttgta caaaaattaa aaaaaaaaaa 2166

aaaaaactcg ag

2178

5

**Claims**

1. A protein nectin-3 consisting of the amino acid sequence of SEQ ID NO: 2.
2. A protein nectin-3 consisting of the amino acid sequence of SEQ ID NO: 4.
3. A protein nectin-3 consisting of the amino acid sequence of SEQ ID NO: 6.
4. A polynucleotide encoding the protein nectin-3 of any of claims 1 to 3.
5. The polynucleotide as claimed in claim 4, which has the base sequence of SEQ ID NO: 1.
6. The polynucleotide as claimed in claim 4, which has the base sequence of SEQ ID NO: 3.
7. The polynucleotide as claimed in claim 4, which has the base sequence of SEQ ID NO: 5.
8. A recombinant vector having the polynucleotide of any of claims 4 to 7.
9. An antibody against the protein nectin-3 of any of claims 1 to 3.

**Patentansprüche**

1. Nectin-3-Protein, bestehend aus der Aminosäuresequenz SEQ ID NO:2.
2. Nectin-3-Protein, bestehend aus der Aminosäuresequenz SEQ ID NO:4.
3. Nectin-3-Protein, bestehend aus der Aminosäuresequenz SEQ ID NO:6.
4. Polynukleotid, welches das Nectin-3-Protein nach einem der Ansprüche 1 bis 3 kodiert.
5. Polynukleotid nach Anspruch 4, das die Basensequenz SEQ ID NO:1 aufweist.
6. Polynukleotid nach Anspruch 4, das die Basensequenz SEQ ID NO:3 aufweist.
7. Polynukleotid nach Anspruch 4, das die Basensequenz SEQ ID NO:5 aufweist.
8. Rekombinanter Vektor, der das Polynukleotid nach einem der Ansprüche 4 bis 7 aufweist.
9. Antikörper gegen das Nectin-3-Protein nach einem der Ansprüche 1 bis 3.

**Revendications**

1. Protéine nectine-3 constituée par la séquence d'acides aminés de SEQ ID n° 2.
2. Protéine nectine-3 constituée par la séquence d'acides aminés de SEQ ID n° 4.
3. Protéine nectine-3 constituée par la séquence d'acides aminés de SEQ ID n° 6.
4. Polynucléotide codant la protéine nectine-3 selon l'une quelconque des revendications 1 à 3.

## EP 1 179 592 B1

5. Polynucléotide selon la revendication 4, qui a la séquence de bases de SEQ ID n° 1.
6. Polynucléotide selon la revendication 4, qui a la séquence de bases de SEQ ID n° 3.
- 5 7. Polynucléotide selon la revendication 4, qui a la séquence de bases de SEQ ID n° 5.
8. Vecteur recombinant ayant le polynucléotide selon l'une quelconque des revendications 4 à 7.
9. Anticorps contre la protéine nectine-3 selon l'une quelconque des revendications 1 à 3.

10

15

20

25

30

35

40

45

50

55

Fig. 1

Nectin-3α	MARTPGPAPLCPGGGKAQLSSAFPPAAGLLLPAPTPPPLLLLIPLLLFSRLCGALAGSI	60
Nectin-3β	MARTPGPAPLCPGGGKAQLSSAFPPAAGLLLPAPTPPPLLLLIPLLLFSRLCGALAGSI	60
Nectin-3γ	MARTPGPAPLCPGGGKAQLSSAFPPAAGLLLPAPTPPPLLLLIPLLLFSRLCGALAGSI	60
Nectin-3α	IVEPHVTAVWGKNVSLKCLIEVNETITQISWEKIHGKSTQTVAVHHPQYGFVQGDYQGR	120
Nectin-3β	IVEPHVTAVWGKNVSLKCLIEVNETITQISWEKIHGKSTQTVAVHHPQYGFVQGDYQGR	120
Nectin-3γ	IVEPHVTAVWGKNVSLKCLIEVNETITQISWEKIHGKSTQTVAVHHPQYGFVQGDYQGR	120
Nectin-3α	VLFKNYSLNDATITLHNIGFSDSGKYICKAVTFPLGNAQSSTTVTLVEPTVSLIKGPD	180
Nectin-3β	VLFKNYSLNDATITLHNIGFSDSGKYICKAVTFPLGNAQSSTTVTLVEPTVSLIKGPD	180
Nectin-3γ	VLFKNYSLNDATITLHNIGFSDSGKYICKAVTFPLGNAQSSTTVTLVEPTVSLIKGPD	180
Nectin-3α	LIDGGNETVAAVCVAAATGKPVAAQIDWEGDLGEMESSTTSFPNETATIVSQYKLFPTRFAR	240
Nectin-3β	LIDGGNETVAAVCVAAATGKPVAAQIDWEGDLGEMESSTTSFPNETATIVSQYKLFPTRFAR	240
Nectin-3γ	LIDGGNETVAAVCVAAATGKPVAAQIDWEGDLGEMESSTTSFPNETATIVSQYKLFPTRFAR	240
Nectin-3α	GRRITCVVKKHPALEKDIRYSFILDIQYAPEVSVTGYDGNWVFGKGVNLKCNADANPPPF	300
Nectin-3β	GRRITCVVKKHPALEKDIRYSFILDIQYAPEVSVTGYDGNWVFGKGVNLKCNADANPPPF	300
Nectin-3γ	GRRITCVVKKHPALEKDIRYSFILDIQYAPEVSVTGYDGNWVFGKGVNLKCNADANPPPF	300
Nectin-3α	KSVWSRLDGGQWPDGLLASDNTLHFVHPLTVNYSGVYVCKVSNLGGQSDQKVIYISDIPPT	360
Nectin-3β	KSVWSRLDGGQWPDGLLASDNTLHFVHPLTVNYSGVYVCKVSNLGGQSDQKVIYISDIPPL	360
Nectin-3γ	KSVWSRLDGGQWPDGLLASDNTLHFVHPLTVNYSGVYVCKVSNLGGQSDQKVIYISDIPPL	360
Nectin-3α	TTTLQPTVQWHSSPADVQDIATEHKKLPFPLSTLATLKDDTIGTIIASVVGALFLVLVS	420
Nectin-3β	TQTSSIAVAGAVIGAVLALFIITVFVTVLLTPRKKRPSYLDKVIDLPPTHKPPVYEERI	420
Nectin-3γ	TQTSSIAVAGAVIGAVLALFIITVFVTVLLTPRKKRPSYLDKVIDLPPTHKPPVYEERI	420
Nectin-3α	LLAGVFCYRRRTFRGDYFAKNYIPPSDMQKESQIDVLHQDELDSPDSVKKENKPNVNN	480
Nectin-3β	PSLPQKDLLGQTEHLPQTQFKEKGAGGLQPSNGPI SRRFDYEDESTMQEDGTQRMCPPLY	480
Nectin-3γ	PSLPQKDLLGQVRALED	438
Nectin-3α	LIRKDYLEEKTOVNNVENLTRFERPMDYEDLKMGMKFVSDERYNESEDGLVSHVDGS	540
Nectin-3β	SOMCHODRSRQHHPRNPERLYINPREHY	510
Nectin-3γ	VISRRWYV	549

Fig.2






Fig.3




Fig.4




Fig.5




Fig. 6




Fig.7




Fig. 8




Fig.9




Fig.10

